• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

精神分裂症患者血浆和血小板中β-苯乙胺的浓度。

Concentrations of beta-phenylethylamine in plasma and plateletes of schizophrenics.

作者信息

Myojin T, Taga C, Tsuji M

机构信息

Department of Neuropsychiatry, Kyoto Prefectural University of Medicine, Japan.

出版信息

Jpn J Psychiatry Neurol. 1989 Jun;43(2):171-6. doi: 10.1111/j.1440-1819.1989.tb02566.x.

DOI:10.1111/j.1440-1819.1989.tb02566.x
PMID:2796027
Abstract

The plasma and platelet PEA levels of 20 normal subjects and 17 schizophrenic patients were investigated using a high-performance liquid chromatography. In the normals the mean plasma and platelet levels of PEA were 4.9 +/- 1.9 ng/ml and 1.78 +/- 1.01 ng/mg protein, respectively, while in the schizophrenics, those were 12.1 +/- 7.9 ng/ml and 0.77 +/- 0.5 ng/mg protein, respectively. The plasma PEA levels of the schizophrenics were significantly higher than those of the normals, and the platelet PEA levels of the schizophrenics were lower than those of the normals.

摘要

采用高效液相色谱法对20名正常人和17名精神分裂症患者的血浆和血小板中苯乙胺(PEA)水平进行了研究。正常人群中,血浆和血小板中PEA的平均水平分别为4.9±1.9纳克/毫升和1.78±1.01纳克/毫克蛋白,而在精神分裂症患者中,这两个数值分别为12.1±7.9纳克/毫升和0.77±0.5纳克/毫克蛋白。精神分裂症患者的血浆PEA水平显著高于正常人,而其血小板PEA水平低于正常人。

相似文献

1
Concentrations of beta-phenylethylamine in plasma and plateletes of schizophrenics.精神分裂症患者血浆和血小板中β-苯乙胺的浓度。
Jpn J Psychiatry Neurol. 1989 Jun;43(2):171-6. doi: 10.1111/j.1440-1819.1989.tb02566.x.
2
Plasma phenylethylamine and phenylalanine in chronic schizophrenic patients.慢性精神分裂症患者的血浆苯乙胺和苯丙氨酸
Biol Psychiatry. 1987 Feb;22(2):194-8. doi: 10.1016/0006-3223(87)90230-7.
3
Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease.帕金森病中的血小板单胺氧化酶B和血浆β-苯乙胺
J Neurol Neurosurg Psychiatry. 2001 Feb;70(2):229-31. doi: 10.1136/jnnp.70.2.229.
4
Urinary trace amine excretion and platelet monoamine oxidase activity in schizophrenia.精神分裂症患者的尿微量胺排泄及血小板单胺氧化酶活性
Psychiatry Res. 1987 Jul;21(3):229-36. doi: 10.1016/0165-1781(87)90027-8.
5
Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls.精神分裂症患者和健康对照者脑脊液中的苯乙胺和苯乙酸
Arch Psychiatr Nervenkr (1970). 1983;232(6):463-71. doi: 10.1007/BF00344060.
6
Determination of beta-phenylethylamine concentrations in human plasma, platelets, and urine and in animal tissues by high-performance liquid chromatography with fluorometric detection.采用高效液相色谱-荧光检测法测定人血浆、血小板、尿液及动物组织中的β-苯乙胺浓度。
Anal Biochem. 1986 Feb 15;153(1):116-20. doi: 10.1016/0003-2697(86)90068-0.
7
Plasma phenylethylamine in schizophrenic patients.精神分裂症患者的血浆苯乙胺
Biol Psychiatry. 1991 Jul 15;30(2):145-50. doi: 10.1016/0006-3223(91)90168-l.
8
Beta-phenylethylamine and noradrenergic function in depression.
Prog Neuropsychopharmacol Biol Psychiatry. 1992 Jan;16(1):45-53. doi: 10.1016/0278-5846(92)90007-2.
9
The measurement of beta-phenylethylamine in human plasma and rat brain.
Anal Biochem. 1994 Aug 15;221(1):42-7. doi: 10.1006/abio.1994.1375.
10
Plasma beta-phenylethylamine in Parkinson's disease.帕金森病中的血浆β-苯乙胺
Kurume Med J. 2000;47(4):267-72. doi: 10.2739/kurumemedj.47.267.

引用本文的文献

1
Engineering ligand-specific biosensors for aromatic amino acids and neurochemicals.工程化用于芳香族氨基酸和神经化学物质的配体特异性生物传感器。
Cell Syst. 2022 Mar 16;13(3):204-214.e4. doi: 10.1016/j.cels.2021.10.006. Epub 2021 Nov 11.
2
Credneramides A and B: neuromodulatory phenethylamine and isopentylamine derivatives of a vinyl chloride-containing fatty acid from cf. Trichodesmium sp. nov.Credneramides A 和 B:一种含氯乙烯脂肪酸的神经调节苯乙胺和异戊胺衍生物,来自 cf. 新 Trichodesmium 属。
J Nat Prod. 2012 Jan 27;75(1):60-6. doi: 10.1021/np200611f. Epub 2011 Dec 12.
3
Trace amine-associated receptor 1-Family archetype or iconoclast?
痕量胺相关受体1——家族原型还是叛逆者?
Pharmacol Ther. 2007 Dec;116(3):355-90. doi: 10.1016/j.pharmthera.2007.06.007. Epub 2007 Jul 17.